Last updated on February 2017

Dose-Escalation Study of FT-2102 as a Single Agent and in Combination With Azacitidine in Patients With AML or MDS With an IDH1 Mutation


Brief description of study

This Phase 1/1b study will utilize a multicenter, open-label dose-escalation design to evaluate the safety, PK, and PD of FT-2102 (single agent) and FT-2102 + azacitidine (combination agent) administered via one or more intermittent dosing schedules. Approximately 48 patients will be enrolled in the dose-escalation portion of this study in one or more schedules followed by approximately 14 patients in expansion cohorts

Clinical Study Identifier: NCT02719574

Contact Investigators or Research Sites near you

Start Over

Tanya Malak

Yale Cancer Center
New Haven, CT United States
  Connect »

Kristen Englund

University of Miami, Sylvester Comprehensive Cancer Center
Miami, FL United States
  Connect »

Sherri Willoughby, MS, RN

Northwestern University
Chicago, IL United States
  Connect »

Melanie Coleman

Indiana Blood and Marrow Transplantation
Indianapolis, IN United States
  Connect »

Hongxia Li

University of Maryland School of Medicine Greenebaum Comprehensive Cancer Center
Baltimore, MD United States
  Connect »

Tony Garn

Karmanos Cancer Institute
Detroit, MI United States
  Connect »

Paul Baskind

New York Medical College
Hawthorne, NY United States
  Connect »

Sarah Leach

Columbia University Medical Center
New York, NY United States
  Connect »

Anh Phung

Weill Cornell Medicine/New York-Presbyterian
New York, NY United States
  Connect »

Jorge Cortes, MD

MD Anderson Cancer Center
Houston, TX United States
  Connect »